Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19) (AtTAC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04453371

Recruitment Status : Withdrawn (Our local committee has denied the approval request)

First Posted : July 1, 2020

Last Update Posted : March 12, 2021

Sponsor:

Collaborator:

Demikhov Municipal Clinical Hospital 68

Information provided by (Responsible Party):

Negovsky Reanimatology Research Institute

Study Description

Brief Summary:

At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. The investigators suggest that thrombolytic therapy may be beneficial when compared to standard care in patients with SARS-CoV-2 and severe respiratory failure.

Condition or disease	Intervention/treatment	Phase
Acute Respiratory Distress Syndrome	Drug: Tissue plasminogen activator Drug: Ringer solution	Phase 3

Show detailed description

Detailed Description:

COVID 19 pandemic is a serious challenge for International medical community. There is lack of knowledge about the nature and character of the lung injury caused by this kind of infection. At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. This progressive endothelial thromboinflammatory syndrome may also involve the microvascular bed of the brain and other vital organs, leading to multiple organ failure and death. Understanding the crucial role of microthrombosis in the genesis of SARS-2-CoV led to a widespread anticoagulant use. Moreover, there is evidence about a possible benefit of thrombolysis in patients with severe COVID-19 pulmonary disease. For Instance, some investigators reported about three patients with COVID 19 lung injury treated with alteplase (tPA). Authors oversaw positive changes in P/F ratio in 3/3 patients, even if in two of these patients changes lasted for a short period. Another investigators reported about the improvements in alveolar ventilation, arterial oxygenation and diminishing in vasopressor's support in 4 patients with SARS-2CoV after thrombolysis. Encouraging results were obtained also by another team in case series of 5 patients who received alteplase. Thus, there is evidence suggesting that thrombolytic therapy may be beneficial when compared to standard care in patients with SARS-CoV-2 and severe respiratory failure. This hypothesis is based on a well-established pathophysiological concept of the occurrence of pulmonary damage as a result of microthrombosis of the lung vessels. Hence, it seems crucial to conduct a randomized clinical trial to test the effectiveness of this treatment.

Objective: To establish whether plasminogen activator (tPA) treatment improves alveolar ventilation P/F (PaO2/FiO2) ratio will be calculated each 6 hours during first 3 days after the end of thrombolysis procedure in patients with an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS).

Methods: Research assistants and/or clinician screen all mechanically ventilated patients for eligibility. Patients satisfying all of the Inclusion and Exclusion Criteria are classified as 'Eligible'. With informed consent from a substitute decision maker or under the decision of Concilium of three independent physicians, Eligible patients are 'Enrolled' into the study. Eligible patients Qualify for Randomization to one of the 2 groups: with or without thrombolytic therapy. In summary, patients are consented and Enrolled prior to Randomization. To enroll or randomize Eligible patients, research coordinators obtain informed consent and access the automated web-based system through Internet based program (available 24 hours/day). Each participating center has a separate computer-generated randomization schedule, with 1:1 (control to intervention) assignment, stratified by center, and using random variable block sizes.

The thrombolysis procedure: In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C. In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.

In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.

Statistical analysis: Primary data analysis will be based on intention to treat (ITT) analysis.

Data will be analyzed also on a modified ITT approach (mITT). Will be included in this analysis only patients with evidence of an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS).

Subgroups analysis: Some pre-defined subgroups analysis will be performed:

Patients with with P/F <200 mmHg>100 mmHg;
Patients with with P/F <100 mmHg;
Patient 65+ group;
Patients under 65 years old. Interim analyses: Interim analyses will not be performed

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	0 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Care Provider)
Primary Purpose:	Treatment
Official Title:	Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (Microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory Syndrome (MicroCLOTS): A Multicentral Randomized Trial (AtTAC-trial)
Estimated Study Start Date :	October 15, 2020
Estimated Primary Completion Date :	January 15, 2021
Estimated Study Completion Date :	February 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COVID-19 (Coronavirus Disease 2019)

Drug Information available for: Plasminogen Alteplase

Genetic and Rare Diseases Information Center resources: Respiratory Distress Syndrome, Infant Acute Respiratory Distress Syndrome Acute Graft Versus Host Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Study group Thrombolysis	Drug: Tissue plasminogen activator In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C. In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level. Other Name: Alteplase
Placebo Comparator: Control group Ringer's solution infusion	Drug: Ringer solution In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group. In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.

Arm

Intervention/treatment

Experimental: Study group

Thrombolysis

Drug: Tissue plasminogen activator

In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.

In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.

Other Name: Alteplase

Placebo Comparator: Control group

Ringer's solution infusion

Drug: Ringer solution

In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.

In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.

Outcome Measures

Primary Outcome Measures :

P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV. [ Time Frame: Each 6 hours during first 3 days after the end of thrombolysis procedure. ]

Secondary Outcome Measures :

Ventilator-free time (days free from MV) for 28 days of observation. [ Time Frame: 28 days ]
Calculated as 28 days - number of days when patient receive any kind of ventilatory support (MV + SV + NIV).

Other Outcome Measures:

Mortality in 28 days and 1 year after randomization despite of the reason. [ Time Frame: 28 days, 1 year after randomization ]
Length of stay in the ICU [ Time Frame: 28 days ]
Number of days when patient was in ICU
Length of stay in hospital [ Time Frame: 28 days ]
Number of days when patient was in hospital
The time needed for "improvement of 2 points" according to WHO "Ordinal Scale for Clinical Improvement" [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 month ]
Chest radiographs on a daily basis and define barotrauma as the presence of new pneumothorax, pneumomediastinum, pneumoperitoneum, or subcutaneous emphysema. [ Time Frame: Daily up to extubation than once a week/or on attending intensivist's discretion up to 1 month ]
Blood Pressure in millimetres of mercury [ Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure. ]
Heart Rate in beats per minute [ Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure. ]
Blood Oxygen Saturation [ Time Frame: Each 4 hours during first 2 weeks after the end of thrombolysis procedure. ]
ECG Q-wave [ Time Frame: Each 24 hours during first 2 weeks after the end of thrombolysis procedure. ]
ECG ST-segment [ Time Frame: Each 24 hours during first 2 weeks after the end of thrombolysis procedure. ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Severe pulmonary coronavirus disease 19 (COVID 19) with suspect for MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome)
P/F ratio <200 mmHg> 70 mmHg
a.) Contrast CT scan positive for pulmonary thrombosis, OR b.) Contrast CT scan negative for pulmonary thrombosis:
- D-Dimer > 10 mcg/mL, OR
- 5 < D-dimer < 10 mcg/mL and C Reactive Protein (CRP) > 100 mg/dL

Exclusion Criteria:

Age < 18
Pregnancy or breastfeeding
Known allergy to iodinated contrast dye
Severe vasoplegic shock: norepinephrine > 300 ng/kg*min
Glomerular Filtration rate < 30 ml/min
Active bleeding or absolute contraindication to anticoagulant therapy (Stroke (intracranial hemorrhage, hemorrhagic stroke), including a history of the last 6 months.; cancer of the Central nervous system and other localities with an increased risk of bleeding, vascular aneurysm, traumatic open heart massage, obstetric delivery, General operations, severe uncontrolled hypertension, gastric ulcer and 12-duodenal ulcer (for 3 months. from the moment of exacerbation), arterial or venous malformations, liver failure, liver cirrhosis, portal hypertension, esophageal varicose veins, active hepatitis).

Contacts and Locations

No Contacts or Locations Provided

More Information

Layout table for additonal information

Responsible Party:	Negovsky Reanimatology Research Institute
ClinicalTrials.gov Identifier:	NCT04453371
Other Study ID Numbers:	tPA-2020
First Posted:	July 1, 2020 Key Record Dates
Last Update Posted:	March 12, 2021
Last Verified:	March 2021

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Negovsky Reanimatology Research Institute:


COVID-19 MicroCLOTS Atypical Acute Respiratory Distress Syndrome

Additional relevant MeSH terms:

Layout table for MeSH terms

COVID-19 Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Acute Lung Injury Syndrome Disease Pathologic Processes Respiratory Tract Infections Infections Pneumonia, Viral Pneumonia Virus Diseases Coronavirus Infections Coronaviridae Infections	Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Lung Injury Tissue Plasminogen Activator Plasminogen Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action

To Top